When was Engage Bio founded?

Engage Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Engage Bio located?

Engage Bio is headquartered in Santa Clara, United States.

How many employees does Engage Bio have?

As of Sep 30, 2026, the latest employee count at Engage Bio is 4.

Is Engage Bio a funded company?

Engage Bio is a funded company, having raised a total of $500K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 29, 2022.

How much is Engage Bio worth?

The last known valuation of Engage Bio was $***** as of Mar 29, 2022.

When was the latest funding round of Engage Bio?

Engage Bio's latest funding was a $***** Grant (prize money) round on Sep 12, 2025, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $7.44B in funding in 2026 to date.

Where does Engage Bio rank among its competitors?

Engage Bio ranks 577th amongst 2499 active competitors, of which 836 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Engage Bio?

Engage Bio's top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Among them, Immuneel secured the most recent funding round in June, 2026.

Engage Bio - 2026 Company Profile, Team, Funding & Competitors

Q: Is Engage Bio an acquired company?

Engage Bio got acquired by Lilly on May 20, 2026.

Engage Bio is an acquired company based in Santa Clara (United States), founded in 2021 by Will Olsen and Kathryn Strobel Kwant. It operates as a Developer of immunotherapies for the treatment of cancer. Engage Bio has raised $500K in funding, with last known valuation of $*****. The company has 2499 active competitors, including 836 funded and 621 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Tango Therapeutics and Elicio.

Company Details

Developer of immunotherapies for the treatment of cancer. The company focuses on the development of mRNA drugs that act as immunotherapies and engage the immune system and redirect it to target cancer.

Website: engagebio.com
Email ID: *****@engagebio.com

Key Metrics

Founded Year

2021

Location

Santa Clara, United States

Stage

Acquired

Total Funding

$500K in 2 rounds

Latest Funding Round

Grant (prize money), Sep 12, 2025, $*****

Last Known Valuation

$***** as on Mar 29, 2022

Investors

WorldQuant Ventures & 4 more

Ranked

577^th among 2499 active competitors

Employee Count

4 as on Sep 30, 2026

Similar Companies

Strand Therapeutics & 31 more

Exit Details

Acquired by Lilly (May 20, 2026)

View Engage Bio's full profile

Engage Bio got acquired by Lilly on May 20, 2026 at an acquisition amount of $*****.

Click here to take a look at Engage Bio's acquisition in detail

Engage Bio has raised a total funding of $500K over 2 rounds. Its first funding round was on Mar 29, 2022. Its latest funding round was a Grant (prize money) round on Sep 12, 2025 for $*****. 1 investor participated in its latest round. Engage Bio has 5 institutional investors.

Here is the list of recent funding rounds of Engage Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2025	9683993	Grant (prize money)	9776838	8153318	3281683	2157501
Mar 29, 2022	3151894	Seed	9205791	4491861	2420526	Y Combinator

Access funding benchmarks and valuations. Sign up today!

View details of Engage Bio's funding rounds and investors

The founders of Engage Bio are Will Olsen and Kathryn Strobel Kwant.

Here are the details of Engage Bio's key team members:

Will Olsen: Co-Founder of Engage Bio and founder of 2 other companies, Luminist and Luminist. They are also an angel investor in 1 startup.
Kathryn Strobel Kwant: Co-Founder and CSO of Engage Bio.

View details of Engage Bio's Founder profiles and Board Members

Engage Bio's employee count trend

Engage Bio has 4 employees as of Sep 26. Here is Engage Bio's employee count trend over the years:

Uncover Engage Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Engage Bio include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of Engage Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
7th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
8th	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	70/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
10th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
577th	Engage Bio 2021, Santa Clara (United States), Acquired	Developer of immunotherapies for the treatment of cancer	$500K	WorldQuant Ventures, California Innovation Fund ... & 3 others	45/100